Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nkarta (NKTX)
NASDAQ:NKTX
Holding NKTX?
Track your performance easily
NKTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.38 - $16.24
Previous Close$2.5
Volume675.83K
Average Volume (3M)736.73K
Market Cap
$175.01M
Enterprise Value-$22.60M
Total Cash (Recent Filing)$283.06M
Total Debt (Recent Filing)$85.45M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Mar 20, 2025EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding70,568,754
10 Day Avg. Volume1,342,442
30 Day Avg. Volume736,733
Standard Deviation0.35
R-Squared0.01
Alpha-0.00320
Financial Highlights & Ratios
Price to Book (P/B)0.41
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.22
Forecast
1Y Price Target
$14.50Price Target Upside494.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Nkarta News
PremiumCompany Announcements
Nkarta, Inc. Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNkarta announced they treated their first patients with lupus, marking a significant step forward in their autoimmune disease program.
Financial PerformanceNkarta ended with $405M and reiterated cash runway guidance into late 2027.
Therapeutic PotentialNkarta is expanding beyond cancer into autoimmune disease, which is seen as prudent given exciting early evidence of potential immune reset.
Bears Say
Clinical DataNkarta will forgo development of NKX019 in NHL, after reviewing the clinical data from the latest cohort of patients and the evolving treatment landscape.
Strategic ShiftNkarta decided not to further invest in another CD19-directed cell therapy for the competitive B-cell lymphoma market, indicating a strategic shift away from these indications.
Trial ResultsPatient enrollment in the NKX101 AML trial was closed after preliminary data showed an aggregate complete remission rate far below the rate observed in the first 6 patients.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NKTX FAQ
What was Nkarta’s price range in the past 12 months?
Nkarta lowest stock price was $2.38 and its highest was $16.24 in the past 12 months.
What is Nkarta’s market cap?
Currently, no data Available
When is Nkarta’s upcoming earnings report date?
Nkarta’s upcoming earnings report date is Mar 20, 2025 which is in 118 days.
How were Nkarta’s earnings last quarter?
Nkarta released its earnings results on Nov 07, 2024. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.368 by -$0.022.
Is Nkarta overvalued?
According to Wall Street analysts Nkarta’s price is currently Undervalued.
Does Nkarta pay dividends?
Nkarta does not currently pay dividends.
What is Nkarta’s EPS estimate?
Nkarta’s EPS estimate is -$0.4.
How many shares outstanding does Nkarta have?
Nkarta has 70,568,756 shares outstanding.
What happened to Nkarta’s price movement after its last earnings report?
Nkarta reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.368. Following the earnings report the stock price went down -2.446%.
Which hedge fund is a major shareholder of Nkarta?
Among the largest hedge funds holding Nkarta’s share is RA Capital Management. It holds Nkarta’s shares valued at 49M.
---
Nkarta Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (494.26% Upside)
$14.50 (494.26% Upside)
Blogger Sentiment
Bullish
NKTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.39%
12-Months-Change
Fundamentals
Return on Equity
-30.40%
Trailing 12-Months
Asset Growth
31.09%
Trailing 12-Months
Company Description
Nkarta
Nkarta Inc is a bio-pharmaceutical company focused on the discovery, development and commercialization of engineered, allogeneic, and off-the-shelf cell therapies to treat cancer.
---
NKTX Stock 12 Month Forecast
Average Price Target
$14.50
▲(494.26% Upside)
Technical Analysis
Best Analysts Covering NKTX
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-8.06%
reiterated a buy rating 15 days ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -8.06% per trade.
---